Literature DB >> 31009795

Efficacy of Fecal Microbiota Transplantation for Clostridium difficile Infection in Children.

Maribeth R Nicholson1, Paul D Mitchell2, Erin Alexander3, Sonia Ballal2, Mark Bartlett3, Penny Becker4, Zev Davidovics4, Michael Docktor2, Michael Dole1, Grace Felix5, Jonathan Gisser6, Suchitra K Hourigan7, M Kyle Jensen8, Jess L Kaplan9, Judith Kelsen10, Melissa Kennedy10, Sahil Khanna3, Elizabeth Knackstedt8, McKenzie Leier2, Jeffery Lewis11, Ashley Lodarek2, Sonia Michail12, Maria Oliva-Hemker5, Tiffany Patton13, Karen Queliza14, George H Russell15, Namita Singh16, Aliza Solomon17, David L Suskind18, Steven Werlin19, Richard Kellermayer14, Stacy A Kahn20.   

Abstract

BACKGROUND & AIMS: Fecal microbiota transplantation (FMT) is commonly used to treat Clostridium difficile infection (CDI). CDI is an increasing cause of diarrheal illness in pediatric patients, but the effects of FMT have not been well studied in children. We performed a multi-center retrospective cohort study of pediatric and young adult patients to evaluate the efficacy, safety, and factors associated with a successful FMT for the treatment of CDI.
METHODS: We performed a retrospective study of 372 patients, 11 months to 23 years old, who underwent FMT at 18 pediatric centers, from February 1, 2004, to February 28, 2017; 2-month outcome data were available from 335 patients. Successful FMT was defined as no recurrence of CDI in the 2 months following FMT. We performed stepwise logistic regression to identify factors associated with successful FMT.
RESULTS: Of 335 patients who underwent FMT and were followed for 2 months or more, 271 (81%) had a successful outcome following a single FMT and 86.6% had a successful outcome following a first or repeated FMT. Patients who received FMT with fresh donor stool (odds ratio [OR], 2.66; 95% CI, 1.39-5.08), underwent FMT via colonoscopy (OR, 2.41; 95% CI, 1.26-4.61), did not have a feeding tube (OR, 2.08; 95% CI, 1.05-4.11), or had 1 less episode of CDI before FMT (OR, 1.20; 95% CI, 1.04-1.39) had increased odds for successful FMT. Seventeen patients (4.7%) had a severe adverse event during the 3-month follow-up period, including 10 hospitalizations.
CONCLUSIONS: Based on the findings from a large multi-center retrospective cohort, FMT is effective and safe for the treatment of CDI in children and young adults. Further studies are required to optimize the timing and method of FMT for pediatric patients-factors associated with success differ from those of adult patients.
Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bacteria; Dysbiosis; Inflammatory Bowel Disease; Microbiome

Year:  2019        PMID: 31009795      PMCID: PMC7549313          DOI: 10.1016/j.cgh.2019.04.037

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  39 in total

1.  Predictors of first recurrence of Clostridium difficile infections in children.

Authors:  Sarah Tschudin-Sutter; Pranita D Tamma; Aaron M Milstone; Trish M Perl
Journal:  Pediatr Infect Dis J       Date:  2014-04       Impact factor: 2.129

2.  Colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection in a child.

Authors:  Stacy A Kahn; Sona Young; David T Rubin
Journal:  Am J Gastroenterol       Date:  2012-12       Impact factor: 10.864

3.  Gut microbiome predictors of treatment response and recurrence in primary Clostridium difficile infection.

Authors:  Sahil Khanna; Emmanuel Montassier; Bradley Schmidt; Robin Patel; Daniel Knights; Darrell S Pardi; Purna Kashyap
Journal:  Aliment Pharmacol Ther       Date:  2016-08-02       Impact factor: 8.171

4.  The epidemiology of community-acquired Clostridium difficile infection: a population-based study.

Authors:  Sahil Khanna; Darrell S Pardi; Scott L Aronson; Patricia P Kammer; Robert Orenstein; Jennifer L St Sauver; W Scott Harmsen; Alan R Zinsmeister
Journal:  Am J Gastroenterol       Date:  2011-11-22       Impact factor: 10.864

5.  An obesity-associated gut microbiome with increased capacity for energy harvest.

Authors:  Peter J Turnbaugh; Ruth E Ley; Michael A Mahowald; Vincent Magrini; Elaine R Mardis; Jeffrey I Gordon
Journal:  Nature       Date:  2006-12-21       Impact factor: 49.962

6.  Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice.

Authors:  Giada De Palma; Michael D J Lynch; Jun Lu; Vi T Dang; Yikang Deng; Jennifer Jury; Genevieve Umeh; Pedro M Miranda; Marc Pigrau Pastor; Sacha Sidani; Maria Ines Pinto-Sanchez; Vivek Philip; Peter G McLean; Moreno-Gabriel Hagelsieb; Michael G Surette; Gabriela E Bergonzelli; Elena F Verdu; Philip Britz-McKibbin; Josh D Neufeld; Stephen M Collins; Premysl Bercik
Journal:  Sci Transl Med       Date:  2017-03-01       Impact factor: 17.956

Review 7.  Fecal microbiota transplantation for recurrent clostridium difficile infection.

Authors:  Lawrence J Brandt; Sheela S Reddy
Journal:  J Clin Gastroenterol       Date:  2011-11       Impact factor: 3.062

8.  The bacteriology of biopsies differs between newly diagnosed, untreated, Crohn's disease and ulcerative colitis patients.

Authors:  Rodrigo Bibiloni; Marco Mangold; Karen L Madsen; Richard N Fedorak; Gerald W Tannock
Journal:  J Med Microbiol       Date:  2006-08       Impact factor: 2.472

Review 9.  Antibiotics associated with increased risk of new-onset Crohn's disease but not ulcerative colitis: a meta-analysis.

Authors:  Ryan Ungaro; Charles N Bernstein; Richard Gearry; Anders Hviid; Kaija-Leena Kolho; Matthew P Kronman; Souradet Shaw; Herbert Van Kruiningen; Jean-Frédéric Colombel; Ashish Atreja
Journal:  Am J Gastroenterol       Date:  2014-09-16       Impact factor: 10.864

10.  National epidemiology of initial and recurrent Clostridium difficile infection in the Veterans Health Administration from 2003 to 2014.

Authors:  Kelly R Reveles; Kenneth A Lawson; Eric M Mortensen; Mary Jo V Pugh; Jim M Koeller; Jacqueline R Argamany; Christopher R Frei
Journal:  PLoS One       Date:  2017-12-07       Impact factor: 3.240

View more
  19 in total

1.  Fecal microbiota transplantation in a toddler after heart transplant was a safe and effective treatment for recurrent Clostridiodes difficile infection: A case report.

Authors:  Joseph A Spinner; Claire E Bocchini; Ruth A Luna; Santosh Thapa; Miriam A Balderas; Susan W Denfield; William J Dreyer; Dorottya Nagy-Szakal; Faith D Ihekweazu; James Versalovic; Tor Savidge; Richard Kellermayer
Journal:  Pediatr Transplant       Date:  2019-10-16

2.  Efficacy and Outcomes of Faecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection in Children with Inflammatory Bowel Disease.

Authors:  Maribeth R Nicholson; Erin Alexander; Sonia Ballal; Zev Davidovics; Michael Docktor; Michael Dole; Jonathan M Gisser; Alka Goyal; Suchitra K Hourigan; M Kyle Jensen; Jess L Kaplan; Richard Kellermayer; Judith R Kelsen; Melissa A Kennedy; Sahil Khanna; Elizabeth D Knackstedt; Jennifer Lentine; Jeffery D Lewis; Sonia Michail; Paul D Mitchell; Maria Oliva-Hemker; Tiffany Patton; Karen Queliza; Sarah Sidhu; Aliza B Solomon; David L Suskind; Madison Weatherly; Steven Werlin; Edwin F de Zoeten; Stacy A Kahn
Journal:  J Crohns Colitis       Date:  2022-06-24       Impact factor: 10.020

Review 3.  Fecal Microbiota Transplantation and Microbial Therapeutics for the Treatment of Clostridioides difficile Infection in Pediatric Patients.

Authors:  Rachel Bernard; Suchitra K Hourigan; Maribeth R Nicholson
Journal:  J Pediatric Infect Dis Soc       Date:  2021-11-17       Impact factor: 5.235

Review 4.  International consensus conference on stool banking for faecal microbiota transplantation in clinical practice.

Authors:  Giovanni Cammarota; Gianluca Ianiro; Colleen R Kelly; Benjamin H Mullish; Jessica R Allegretti; Zain Kassam; Lorenza Putignani; Monika Fischer; Josbert J Keller; Samuel Paul Costello; Harry Sokol; Patrizia Kump; Reetta Satokari; Stacy A Kahn; Dina Kao; Perttu Arkkila; Ed J Kuijper; Maria J Gt Vehreschild; Cristina Pintus; Loris Lopetuso; Luca Masucci; Franco Scaldaferri; E M Terveer; Max Nieuwdorp; Antonio López-Sanromán; Juozas Kupcinskas; Ailsa Hart; Herbert Tilg; Antonio Gasbarrini
Journal:  Gut       Date:  2019-09-28       Impact factor: 23.059

5.  The intestinal microbiota contributes to the growth and physiological state of muscle tissue in piglets.

Authors:  Renli Qi; Jing Sun; Xiaoyu Qiu; Yong Zhang; Jing Wang; Qi Wang; Jinxiu Huang; Liangpeng Ge; Zuohua Liu
Journal:  Sci Rep       Date:  2021-05-27       Impact factor: 4.379

6.  Current Challenges in Fecal Microbiota Transplantation for Clostridioides difficile Infection in Children.

Authors:  Maribeth R Nicholson; Suchitra K Hourigan; Maire Conrad; Alka Goyal; Kyle Jensen; Judith Kelsen; Melissa Kennedy; Madison Weatherly; Stacy A Kahn
Journal:  Am J Gastroenterol       Date:  2021-09-01       Impact factor: 12.045

7.  Clostridioides difficile Infection in Pediatric Inflammatory Bowel Disease: A Clinician's Dilemma.

Authors:  Máire A Conrad; Judith R Kelsen
Journal:  J Pediatric Infect Dis Soc       Date:  2021-11-17       Impact factor: 5.235

8.  Updates and Challenges in Fecal Microbiota Transplantation for Clostridioides difficile Infection in Children.

Authors:  Suchitra K Hourigan; Maribeth R Nicholson; Stacy A Kahn; Richard Kellermayer
Journal:  J Pediatr Gastroenterol Nutr       Date:  2021-10-01       Impact factor: 3.288

9.  A Distinct Microbiome Signature in Posttreatment Lyme Disease Patients.

Authors:  Madeleine Morrissette; Norman Pitt; Antonio González; Philip Strandwitz; Mariaelena Caboni; Alison W Rebman; Rob Knight; Anthony D'Onofrio; John N Aucott; Mark J Soloski; Kim Lewis
Journal:  mBio       Date:  2020-09-29       Impact factor: 7.867

10.  Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry.

Authors:  Colleen R Kelly; Eugene F Yen; Ari M Grinspan; Stacy A Kahn; Ashish Atreja; James D Lewis; Thomas A Moore; David T Rubin; Alison M Kim; Sonya Serra; Yanina Nersesova; Lydia Fredell; Dea Hunsicker; Daniel McDonald; Rob Knight; Jessica R Allegretti; Joel Pekow; Imad Absah; Ronald Hsu; Jennifer Vincent; Sahil Khanna; Lyn Tangen; Carl V Crawford; Mark C Mattar; Lea Ann Chen; Monika Fischer; Razvan I Arsenescu; Paul Feuerstadt; Jonathan Goldstein; David Kerman; Adam C Ehrlich; Gary D Wu; Loren Laine
Journal:  Gastroenterology       Date:  2020-10-01       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.